FK506-binding protein 12–mechanistic target of rapamycin complex (FKBP12–mTOR complex) (FKBP12–mTOR complex)

The FK506-binding protein 12–mechanistic target of rapamycin (FKBP12–mTOR) complex is a pivotal signaling assembly that regulates fundamental cellular processes including growth, metabolism, and protein synthesis [1, 2]. This complex is primarily formed when macrolide drugs such as rapamycin (sirolimus) or its analogs (rapalogs) bind to the cytosolic immunophilin FKBP12; this binary complex then associates with the FKBP-rapamycin binding (FRB) domain of the mTOR kinase [3, 5]. This interaction allosterically inhibits the mTOR Complex 1 (mTORC1) by sterically blocking the recruitment of substrates like S6K1 and 4E-BP1 and destabilizing the complex's integrity [2, 5]. Dysregulation of the mTOR pathway is a hallmark of numerous diseases, particularly cancers where hyperactivation drives uncontrolled proliferation, and in genetic disorders like tuberous sclerosis [4]. Consequently, the FKBP12–mTOR complex serves as a major therapeutic target for immunosuppression in organ transplantation and as a cytostatic target in oncology [3, 4]. However, therapeutic challenges include the development of resistance through feedback loops and significant side effects such as metabolic disturbances and immunosuppression-related infections [3, 4].

Other names

FKBP12-rapamycin-mTOR complexFKBP12-mTORC1 complexFKBP12-FRB complexFKBP1A-mTOR complexFKBP12-RAFT1 complexFKBP12-FRAP complex

Allosteric inhibition of mTORC1 through the formation of a ternary complex with FKBP12 and the FRB domain of mTOR, which sterically blocks substrate recruitment and destabilizes the complex [2, 5].